Ignite Creation Date:
2025-12-24 @ 9:07 PM
Ignite Modification Date:
2025-12-28 @ 8:09 AM
Study NCT ID:
NCT02536404
Status:
COMPLETED
Last Update Posted:
2021-11-26
First Post:
2015-08-24
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Sponsor:
Arena Pharmaceuticals
Organization:
Study Overview
Official Title:
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status:
COMPLETED
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: